<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437891</url>
  </required_header>
  <id_info>
    <org_study_id>GWF001</org_study_id>
    <nct_id>NCT01437891</nct_id>
  </id_info>
  <brief_title>Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)</brief_title>
  <acronym>GWF001</acronym>
  <official_title>An Open-label Clinical Outcomes Study to Determine the Safety and Efficacy of Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder and Gulf War Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stephanie Pavlik</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targeted Medical Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label clinical outcomes study to determine the safety and efficacy of Sentra AM® and
      Sentra PM® for post-traumatic stress disorder (PTSD) and Gulf War fibromyalgia (GWF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Male and female military veterans age 18 to 75 experiencing moderate to severe PTSD symptoms
      including cognitive dysfunction, sleep disorders and mood disorders.

      Open-label internet questionnaire-based clinical outcomes study. 250 subjects. 60 days from
      enrollment initiation to completion and study close. Sentra AM- two capsules given orally
      once daily in the morning for 30 days. Sentra PM- two capsules given orally once daily thirty
      minutes before bedtime for 30 days.

      To measure improvement in quality of life determined by the change in short form-36 (SF-36)
      general health survey.

      Improvements in daytime sleepiness determined by the Epworth Sleepiness Scale (ESS),
      improvement in cognitive and emotional function using the Cognitive emotion regulation
      questionnaire - short (CERQ-Short), change in PTSD symptoms with the Primary Care - PTSD
      (PC-PTSD), Psychopathy Checklist- Military (PCL-M). Heart rate variability (HRV) data
      variation will be measured in a group of twenty subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SF-36 general health survey</measure>
    <time_frame>Baseline and Day 30</time_frame>
    <description>A general health questionnaire to measure quality of life. Change from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>Baseline and Day 30</time_frame>
    <description>Improvements in daytime sleepiness determined by the Epworth Sleepiness Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CERQ-short</measure>
    <time_frame>Baseline and Day 30</time_frame>
    <description>Assessment of cognitive function. Change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCL-Military</measure>
    <time_frame>Baseline and Day 30</time_frame>
    <description>Changes in symptoms of military specific PTSD.</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <condition>Persian Gulf Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female military veterans age 18 to 75 experiencing moderate to severe PTSD
        symptoms including cognitive dysfunction, sleep disorders and mood disorders.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. United States military veterans reporting PTSD and/or Gulf War Illness symptoms at
             least three months after return from duty.

          2. Men and non-pregnant, non-lactating women over the age of 18 and under the age of 75,
             able to read and understand English-language informed consent.

          3. Men and women of child-bearing potential willing to use adequate contraception, not to
             become pregnant or impregnate their partner for the study duration.

          4. Patients who will continue on a stable dose (no less than three months) of other
             medications they are taking and maintain the same dose throughout the duration of the
             study.

          5. Patients willing to commit to completing all clinical questionnaires and guidelines
             during study-related procedures.

        Exclusion Criteria:

          1. Patients who have previously taken Sentra AM or Sentra PM.

          2. Patients not fluent in English.

          3. Participation in a clinical trial within one (1) month prior to screening.

          4. Uncontrolled or unstable serious cardiovascular, pulmonary, gastrointestinal,
             endocrine or neurologic disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Shell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Targeted Medical Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Targeted Medical Pharma</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Targeted Medical Pharma</investigator_affiliation>
    <investigator_full_name>Stephanie Pavlik</investigator_full_name>
    <investigator_title>Clinical Research Associate</investigator_title>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Military veteran</keyword>
  <keyword>Gulf War</keyword>
  <keyword>Fibromyalgia</keyword>
  <keyword>Gulf War Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Persian Gulf Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

